Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration

E. Rechtman, R. P. Danis, L. M. Pratt, Alon Harris

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Aims: To report the effects of intravitreal triamcinolone acetonide (iTAAC) injections as an adjunctive treatment to photodynamic therapy (PDT) with verteporfin for new subfoveal choroidal neovascolarisation (CNV) in age related macular degeneration (AMD). Methods: We retrospectively reviewed the records of all AMD patients who had iTAAC within 6 weeks of their first PDT and had a follow up of one year or longer. The proportion of eyes after one year follow up that lost or gained ≥15 and ≥30 ETDRS letters, baseline and one year lesion greatest linear dimension (GLD), number of PDTs, and side effects were assessed. Results: Fourteen patients were evaluated. Eleven received one initial combined treatment and three received an additional combined treatment after 6 months. Median follow up was 18 months (range 12 to 25 months). Overall, 7% gained ≥30 letters, 50% maintained stable vision, 14% lost 15-29 letters, and 29% lost ≥30 letters. Overall, mean GLD increased from 2580 (SD 1088) μm to 3946 (SD 1503) μm (p = 0.01). The mean number of PDTs during the first year was 2.57. Side effects were mild intraocular pressure elevation in 28.5% and cataract progression in 50% of phakic eyes. Conclusions: iTAAC with PDT in AMD was found to be relatively safe and had reasonable results for lesions with some classic component.

Original languageEnglish
Pages (from-to)344-347
Number of pages4
JournalBritish Journal of Ophthalmology
Volume88
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Triamcinolone
Triamcinolone Acetonide
Choroidal Neovascularization
Photochemotherapy
Macular Degeneration
Intraocular Pressure
Cataract
Therapeutics
Injections
1-phenyl-3,3-dimethyltriazene

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. / Rechtman, E.; Danis, R. P.; Pratt, L. M.; Harris, Alon.

In: British Journal of Ophthalmology, Vol. 88, No. 3, 03.2004, p. 344-347.

Research output: Contribution to journalArticle

@article{35c2fe68374a4491b2ecab4e161dc182,
title = "Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration",
abstract = "Aims: To report the effects of intravitreal triamcinolone acetonide (iTAAC) injections as an adjunctive treatment to photodynamic therapy (PDT) with verteporfin for new subfoveal choroidal neovascolarisation (CNV) in age related macular degeneration (AMD). Methods: We retrospectively reviewed the records of all AMD patients who had iTAAC within 6 weeks of their first PDT and had a follow up of one year or longer. The proportion of eyes after one year follow up that lost or gained ≥15 and ≥30 ETDRS letters, baseline and one year lesion greatest linear dimension (GLD), number of PDTs, and side effects were assessed. Results: Fourteen patients were evaluated. Eleven received one initial combined treatment and three received an additional combined treatment after 6 months. Median follow up was 18 months (range 12 to 25 months). Overall, 7{\%} gained ≥30 letters, 50{\%} maintained stable vision, 14{\%} lost 15-29 letters, and 29{\%} lost ≥30 letters. Overall, mean GLD increased from 2580 (SD 1088) μm to 3946 (SD 1503) μm (p = 0.01). The mean number of PDTs during the first year was 2.57. Side effects were mild intraocular pressure elevation in 28.5{\%} and cataract progression in 50{\%} of phakic eyes. Conclusions: iTAAC with PDT in AMD was found to be relatively safe and had reasonable results for lesions with some classic component.",
author = "E. Rechtman and Danis, {R. P.} and Pratt, {L. M.} and Alon Harris",
year = "2004",
month = "3",
doi = "10.1136/bjo.2003.027177",
language = "English",
volume = "88",
pages = "344--347",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration

AU - Rechtman, E.

AU - Danis, R. P.

AU - Pratt, L. M.

AU - Harris, Alon

PY - 2004/3

Y1 - 2004/3

N2 - Aims: To report the effects of intravitreal triamcinolone acetonide (iTAAC) injections as an adjunctive treatment to photodynamic therapy (PDT) with verteporfin for new subfoveal choroidal neovascolarisation (CNV) in age related macular degeneration (AMD). Methods: We retrospectively reviewed the records of all AMD patients who had iTAAC within 6 weeks of their first PDT and had a follow up of one year or longer. The proportion of eyes after one year follow up that lost or gained ≥15 and ≥30 ETDRS letters, baseline and one year lesion greatest linear dimension (GLD), number of PDTs, and side effects were assessed. Results: Fourteen patients were evaluated. Eleven received one initial combined treatment and three received an additional combined treatment after 6 months. Median follow up was 18 months (range 12 to 25 months). Overall, 7% gained ≥30 letters, 50% maintained stable vision, 14% lost 15-29 letters, and 29% lost ≥30 letters. Overall, mean GLD increased from 2580 (SD 1088) μm to 3946 (SD 1503) μm (p = 0.01). The mean number of PDTs during the first year was 2.57. Side effects were mild intraocular pressure elevation in 28.5% and cataract progression in 50% of phakic eyes. Conclusions: iTAAC with PDT in AMD was found to be relatively safe and had reasonable results for lesions with some classic component.

AB - Aims: To report the effects of intravitreal triamcinolone acetonide (iTAAC) injections as an adjunctive treatment to photodynamic therapy (PDT) with verteporfin for new subfoveal choroidal neovascolarisation (CNV) in age related macular degeneration (AMD). Methods: We retrospectively reviewed the records of all AMD patients who had iTAAC within 6 weeks of their first PDT and had a follow up of one year or longer. The proportion of eyes after one year follow up that lost or gained ≥15 and ≥30 ETDRS letters, baseline and one year lesion greatest linear dimension (GLD), number of PDTs, and side effects were assessed. Results: Fourteen patients were evaluated. Eleven received one initial combined treatment and three received an additional combined treatment after 6 months. Median follow up was 18 months (range 12 to 25 months). Overall, 7% gained ≥30 letters, 50% maintained stable vision, 14% lost 15-29 letters, and 29% lost ≥30 letters. Overall, mean GLD increased from 2580 (SD 1088) μm to 3946 (SD 1503) μm (p = 0.01). The mean number of PDTs during the first year was 2.57. Side effects were mild intraocular pressure elevation in 28.5% and cataract progression in 50% of phakic eyes. Conclusions: iTAAC with PDT in AMD was found to be relatively safe and had reasonable results for lesions with some classic component.

UR - http://www.scopus.com/inward/record.url?scp=1542407176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542407176&partnerID=8YFLogxK

U2 - 10.1136/bjo.2003.027177

DO - 10.1136/bjo.2003.027177

M3 - Article

C2 - 14977766

AN - SCOPUS:1542407176

VL - 88

SP - 344

EP - 347

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 3

ER -